Ett urval av publicerade artiklar

**Symtomkontroll**


**Byte från konventionell levodopa till Stalevo**


**Byte från konventionell levodopa och entakapon till Stalevo**


**Arbetsliv**


**Livskvalitet**

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s disease patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

Efficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Prog Neuro-Psychopharmacol Biol Psychiatry 2003;27:963-971.

Durif F, Devaux I, Pere JJ, et al
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Eur Neurol 2001;45:111-118.

Compliance/Följsamhet
Grosset KA, Reig JL, Grosset DG.
Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease.

Farmakokinetik
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
Comparison of the pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Stocchi F.
The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations.

Graviditet
Lindh J.
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.

Övrigt/Reviews
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong.
Clin Interv Aging 2010;5:229-238.
Seeberger LC, Hauser RA.
Levodopa/carbidopa/entacapone in Parkinson’s disease.
Brooks DJ.
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.
Gordin A, Brooks DJ.
Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson’s disease.
Silver DE.
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).